Press Releases Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
10.30 ^USD	-9.33%		-14.81%	-54.77%

12-05	Top Premarket Decliners	MT
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI

Press Releases

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	11-11	AQ
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results	11-06	AQ
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025	10-30	AQ
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study	10-28	AQ
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome	10-21	AQ
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million	10-13	AQ
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million	10-10	AQ
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome	09-09	AQ
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome	08-21	AQ
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy	08-18	AQ
Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton	08-12	AQ
Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update	08-07	AQ
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025	07-31	AQ
Quoin Pharmaceuticals Provides Product Portfolio Update	07-29	AQ
Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases	06-26	AQ
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	06-24	AQ
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	05-22	AQ
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome	05-20	AQ
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO - Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge - More Stocks Inside	05-15	AQ
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	05-14	AQ
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results	05-13	AQ
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025	05-06	AQ
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule	04-30	AQ
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign	04-10	AQ
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient	04-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Press Releases

Filters